The FDA has given Dupixent the go-ahead as a treatment for nasal polyps.
Dupixent, an injectable drug sold by Regeron Pharmaceuticals and Sanofi, was first approved in 2017 for eczema and then in 2018 for moderate-to-severe asthma. The new indication will allow doctors to also prescribe Dupixent for nasal polyps — painful growths associated with chronic rhinosinusitis, which causes inflammation in the cavities around nasal passages. Dupixent is the first biologic to win approval for the condition.
Regeneron Pharmaceuticals and Sanofi pulled in about $896 million in sales for Dupixent last year. The expanded indication will allow the companies to target the 55,000 to 90,000 adults who suffer from nasal polyps that have not responded well to steroids or surgery. According to data from Refinitiv, sales for Dupixent could reach $1.86 billion this year.
Read the full Reuters report.